{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:21:26Z","timestamp":1747200086066,"version":"3.40.5"},"reference-count":21,"publisher":"Media Sphere Publishing House","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Objective. To evaluate the effect of discontinuation or prolongation of DMT on the activity of the disease during pregnancy and in the postpartum period in patients with aggressive MS from the Moscow region. Material and methods. The study included female patients with an aggressive course of MS receiving DMT at the time of pregnancy. The patients were followed-up for the period 2016 to February 2024. Results. There were 17 cases of pregnancy during natalizumab (NZ) therapy; discontinuation of therapy in the first trimester of pregnancy provoked a resumption of disease activity in half of the patients. There were no exacerbations in patients whose therapy was prolonged until the 34th week of pregnancy. In 5 patients receiving fingolimod (FGL), therapy was discontinued upon the establishment of pregnancy, which caused the resumption of disease activity in three out of 5 cases. In 3 patients receiving anti-B-cell therapy, pregnancy occurred within a few months after the next infusion, there were no exacerbations during pregnancy. Conclusion. The cancellation of NS therapy in the early stages of pregnancy in most cases leads to the resumption of disease activity during pregnancy. Exacerbations in the postpartum period also correlated with early discontinuation of therapy and with a long period before the restart of infusions. Prolongation of infusions to 30-34 weeks of pregnancy contributed to stabilization of the condition throughout the perinatal period. Discontinuation of FGL therapy at the onset of pregnancy increased the risk of repeated relapses of the disease, up to the development of inflammatory immune restoration syndrome during pregnancy and contributed to the increase in disability in the postpartum period.<\/jats:p>","DOI":"10.17116\/jnevro202412407272","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:44:38Z","timestamp":1724395478000},"page":"72","source":"Crossref","is-referenced-by-count":0,"special_numbering":"Vyp. 2","title":["Experience in the management of pregnant patients with highly active multiple sclerosis in the Moscow region"],"prefix":"10.17116","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-1859","authenticated-orcid":false,"given":"D.M.","family":"Yakushin","sequence":"first","affiliation":[{"name":"Vladimirskiy Moscow Regional Research Clinical Institute","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-9443","authenticated-orcid":false,"given":"I.O.","family":"Shtang","sequence":"additional","affiliation":[{"name":"Vladimirskiy Moscow Regional Research Clinical Institute","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-309X","authenticated-orcid":false,"given":"T.I.","family":"Yakushina","sequence":"additional","affiliation":[{"name":"Vladimirskiy Moscow Regional Research Clinical Institute","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8706-7317","authenticated-orcid":false,"given":"S.V.","family":"Kotov","sequence":"additional","affiliation":[{"name":"Vladimirskiy Moscow Regional Research Clinical Institute","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202412407272-1","doi-asserted-by":"publisher","DOI":"10.18786\/2072-0505-2015-39-82-89"},{"key":"key-10.17116\/jnevro202412407272-2","unstructured":"Popova EV, Kukel\u2019 TM, Muravin AI, et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10-2):52-56. (In Russ.)"},{"key":"key-10.17116\/jnevro202412407272-3","unstructured":"Clinical recommendations. Multiple sclerosis. 2022. (In Russ.). https:\/\/cr.minzdrav.gov.ru\/clin_recomend"},{"key":"key-10.17116\/jnevro202412407272-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390501"},{"key":"key-10.17116\/jnevro202412407272-5","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.973848"},{"key":"key-10.17116\/jnevro202412407272-6","unstructured":"Devonshire V, Duguette H, Dwosh E, et al. The immune system and hormones: review and relevance to pregnancy and contraception in women with MS. Int MS J. 2003;10(2):45-50"},{"key":"key-10.17116\/jnevro202412407272-7","unstructured":"Dwosh E, Guimond C, Duguette P, et al. The interaction of MS and pregnancy: a critical review. Int MS J. 2003;10(2):39-42"},{"key":"key-10.17116\/jnevro202412407272-8","unstructured":"FDA pregnancy categories. The link is active on 04\/01\/2024.  https:\/\/www.drugs.com\/pregnancy-categories.html"},{"key":"key-10.17116\/jnevro202412407272-9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103963"},{"key":"key-10.17116\/jnevro202412407272-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2019.e00162"},{"key":"key-10.17116\/jnevro202412407272-11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.04.003"},{"key":"key-10.17116\/jnevro202412407272-12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56020049"},{"key":"key-10.17116\/jnevro202412407272-13","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00804-6"},{"key":"key-10.17116\/jnevro202412407272-14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44750"},{"key":"key-10.17116\/jnevro202412407272-15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.209"},{"key":"key-10.17116\/jnevro202412407272-16","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01106-6"},{"key":"key-10.17116\/jnevro202412407272-17","unstructured":"Hutchinson M. Pregnancy in MS. Int MS J. 1997;3(3):81-84"},{"key":"key-10.17116\/jnevro202412407272-18","unstructured":"Instructions for the medical use of the drug Gilenia LP 008272\/10 dated 06\/04\/2021. (In Russ.)"},{"key":"key-10.17116\/jnevro202412407272-19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/103.2.281"},{"key":"key-10.17116\/jnevro202412407272-20","unstructured":"Instructions for the medical use of the drug Ocrevus LP 004503 dated 05\/01\/2023. (In Russ.)"},{"key":"key-10.17116\/jnevro202412407272-21","unstructured":"Lopes Leon S. Effect of finfolimod on pregnancy outcomes in patients with multiple sclerosis. Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 11\u201413 September 2019; Stockholm, Sweden, Poster P411"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:44:12Z","timestamp":1745387052000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2024\/7-2\/1199772982024072072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8,23]]}},"alternative-id":["10.17116\/jnevro202412407272"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202412407272","relation":{},"ISSN":["1997-7298"],"issn-type":[{"type":"print","value":"1997-7298"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}